In a report published Friday, Citigroup reiterated its Neutral rating on C.R. Bard (NYSE: BCR ), but lowered its price target from $103.00 to $99.00. Citigroup noted, “We rate shares of C.R. Bard Neutral. Bard re-emerged as a value play in the med tech space after its pending merger with